Loading…
← CockpitCompetitor Analysis › NNNN Anbio Biotechnology Class AOpen in the cockpit ↗

Anbio Biotechnology Class ANNNNCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum laggard 5
Mkt cap
$518M
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$139,712
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 20.0%
Hurdle
n/a
no reverse DCF
Close · USD$3.60
1D-1.4%
1W-11.1%
1M-3.5%
3M-50.9%
6M-88.7%
YTD-88.0%
1Y-86.8%
ATR %11.7%
Beta0.47
52w lowhigh92.0% off high

What Anbio Biotechnology does

Employees: 27

Anbio Biotechnology at a glance

Size Anbio Biotechnology (NNNN) is a United States Health Care company (Medical Specialties) with a market value of $518M, the 2650th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.60 on 18 Nov 2026.

Performance Over six months the shares fell 88.7%, against -19.1% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 10.2% over the last twelve months (peer median +3.9%); the operating margin is 66.7% (peer median 2.2%).

Short interest Short interest is 0.1% of the free float (30 Oct 2026).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026Peer median 82NNNN 12
Six months, rebased to 100: Anbio Biotechnology against the median of its 20 peers (local-currency closes).

Anbio Biotechnology financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/a$9.76M$8.85M$7.26M$24.7M
Revenue growth—+10%+22%-71%—
Gross profitn/a$8.51M$6.37M$3.63M$13.2M
EBITDAn/a$6.51M$2.16M$2.13M$10.7M
Net incomen/a$7.23M$2.57M$2.44M$10.5M
Free cash flown/a-$7.61M$2.25M$971,240$4.72M
Capital expendituren/a$0$0$0$0
Total debtn/a$0$0$0$0

Quarterly statements and history in the cockpit →

Anbio Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%3004393006397979AVR688075RCELMYGNZJYL688298688580MEDX300869603520002932603122CEVINNNN6-month return →1-month return →
Up and to the right = strong over both horizons. Anbio Biotechnology is the large dot.

Anbio Biotechnology competitors and peer comparison

How Anbio Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Anbio Biotechnology against its 20 peers (data as of 18 Nov 2026)
MeasureNNNNPeer medianRank in peer set
1-month return-3.5%-6.7%9th highest of 21
6-month return-88.7%-19.1%lowest of 21
Distance from 52-week high-92.0%-40.9%lowest of 21
Revenue growth (TTM)+10.2%+3.9%5th highest of 21
Operating margin66.7%2.2%highest of 21
Net debt / EBITDA-2.1×-1.2×2nd least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%1.5×6.0%-7.7%
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%3.9×0.4%-13.2%
Shofu 7979.TJapan$510M+32%+9%14%1.6×n/an/a
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%125.0×n/an/a
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%5.4×30.8%-18.6%
AVITA Medical RCELUnited States$529M+290%+17%-34%6.7×n/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%0.8×n/an/a
Jin Medical International ZJYLUnited States$532M+47%-14%2%26.5×n/an/a
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%1.6×n/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%5.3×20.1%+4.2%
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%2.6×10.2%+6.5%
medmix MEDX.SWSwitzerland$494M+11%-7%6%1.4×4.5%+5.0%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%5.5×15.0%-19.8%
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%2.2×n/an/a
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%1.3×-6.5%-4.3%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%7.0×4.3%+24.4%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%3.1×55.3%-4.7%
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%5.9×n/an/a
CellaVision CEVI.STSweden$477M+64%+2%23%6.1×7.1%+10.0%

Questions

Which companies are Anbio Biotechnology's closest peers?
The cockpit's peer set: MedicalSystem Biotechnology (300439.SZ), Guangdong Hybribio Biotech (300639.SZ), Shofu (7979.T), Anteris Technologies Global (AVR), Assure Tech (Hangzhou) (688075.SS), AVITA Medical (RCEL), Myriad Genetics (MYGN), Jin Medical International (ZJYL).
How has Anbio Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -88.7% against -19.1% for the median peer; over one year -86.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.